Intrexon Corp (NASDAQ:XON) Q2 2019 Earnings Conference Call - Final Transcript
Aug 08, 2019 • 05:30 pm ET
Good afternoon, and welcome to the Intrexon Corporation Second Quarter and First Half 2019 Financial Results Conference Call. [Operator Instructions] Please note, this event is being recorded. I would now like to turn the conference over to Steven Harasym, Vice President of Investor Relations. Please go ahead.
Thank you, Gary. Welcome to Intrexon's Second Quarter 2019 Investor Call. I'm Steve Harasym, Vice President of Investor Relations, and I'm joined by Thomas Bostick, Intrexon's Chief Operating Officer and our CEO, R.J. Kirk. During this call, we will make various forward-looking statements. Investors are cautioned that our forward-looking statements are based on current expectations and are subject to risks and uncertainties. A number of factors could cause actual results to differ materially from those indicated by our forward-looking statements. Please read the safe harbor statement contained in the earnings release as well as Intrexon's most recent SEC filings for a more complete description. On today's call, we will provide an update on our progress, including updates on clinical developments and transactions. We will conclude with a Q&A session.
I would like to begin by providing an overview on some of our health programs.
Next slide. Precigen continues to advance its clinical and preclinical portfolio in oncology, autoimmune disorders and infectious diseases. Most notably, we now have patients in the clinic using our UltraCART therapeutic platform, which are first-in-class investigational cell-pair therapies, that can be rapidly administered following nonviral gene transfer. In June, we announced that PRGN-3006 began dosing in the Phase I/Ib study for patients with AML and higher-risk MDS and this week, we announced dosing in the Phase I study of PRGN-3005 for patients with advanced recurrent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer. With dosing underway in two trials using our UltraCART therapeutic platform, we believe we are one step closer to disrupting the current CAR T treatment landscape, with the goals of increasing patient access through shortened manufacturing time, decreasing manufacturing-related cost and improving outcomes using advanced approaches for precise tumor targeting and control of the immune system. We look forward to providing you with updates in the coming months.
Next slide. Another Precigen program, which continues to advance is PRGN-5001, which is our multifunctional therapeutic candidate, designed to treat solid tumors. Updated preclinical models in head and neck cancer shown here, demonstrate potential superiority to approve an anti-PD-1 checkpoint inhibitors.
Next slide. Outside of Precigen, I will provide a few updates on other therapeutic programs. One is our majority-owned subsidiary Triple-Gene, which is working on potential treatments for heart failure. We continue to move forward, evaluating INXN-4001, which is the world's first investigational Triple-Gene drug candidate, to target heart failure, which is a leading cause of death in humans. We aim to address the limitations of current treatments, with our investigational, nonviral plasmid-based therapeutic candidate, which is designed to drive expression of three cardiac effector genes involved in heart failure. Triple-Gene completed dosing in the first cohort of advanced heart failure patients, maintained on left ventricular assist devices.